The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 25, 2023
Filed:
Apr. 14, 2017
The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);
The University of Kansas, Lawrence, KS (US);
The University of North Carolina AT Chapel Hill, Chapel Hill, NC (US);
David R. Sibley, Bethesda, MD (US);
Amy Elizabeth Moritz, Bethesda, MD (US);
R. Benjamin Free, Bethesda, MD (US);
Joseph P. Steiner, Bethesda, MD (US);
Noel Terrence Southall, Rockville, MD (US);
Marc Ferrer, Rockville, MD (US);
Xin Hu, Rockville, MD (US);
Warren S. Weiner, Boston, MA (US);
Jeffrey Aubé, Chapel Hill, NC (US);
Kevin Frankowski, Chapel Hill, NC (US);
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Bethesda, MD (US);
THE UNIVERSITY OF KANSAS, Lawrence, KS (US);
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, Chapel Hill, NC (US);
Abstract
The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R, R, R, and Rare defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.